<DOC>
	<DOCNO>NCT01122524</DOCNO>
	<brief_summary>The primary objective study determine performance characteristic ( sensitivity specificity ) Verinata Health Test detect fetal Trisomy 21 ( T21 ) compare karyotype result obtain amniocentesis chorionic villus sampling ( CVS ) . Secondary objective assess performance test detect male gender ( XY ) less common aneuploidy ( Trisomy 13 ( T13 ) , Trisomy 18 ( T18 ) , Turner Syndrome ( 45 , X ) ) compare clinical fetal karyotype .</brief_summary>
	<brief_title>MatErnal BLood IS Source Accurately Diagnose Fetal Aneuploidy</brief_title>
	<detailed_description />
	<mesh_term>Aneuploidy</mesh_term>
	<criteria>Age 18 year old Clinically confirm viable pregnancy time enrollment Clinically determine gestational age 8 wks , 0 day 22 wks , 0 day Referred plan undergo CVS amniocentesis procedure due risk fetal aneuploidy base protocolspecified clinical indicator Able provide consent participation use language appropriate form consent process Invasive prenatal procedure ( amniocentesis CVS ) perform prior enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Trisomy 21</keyword>
</DOC>